Post-COVID-19 Supply Chain

How are you rethinking your supply chain and operational fitness in light of the COVID-19 pandemic?

Drug Pricing Solutions

What steps is your company taking to address drug pricing issues?

Drug Molecules

What two or three drug molecules do you identify as having had the greatest impact on society? What about on the pharmaceutical industry?

COVID-19

What is your perspective on how the pharma industry has responded to the COVID-19 pandemic? What lessons have been learned?

Drug Molecules

What two or three drug molecules do you identify as having had the greatest impact on society? What about on the pharmaceutical industry?

M&A

How would you characterize the current landscape of M&A activity in the pharmaceutical/biopharmaceutical industry?

Roundtable Topics

Post-COVID-19 Supply Chain

Drug Pricing Solutions

COVID-19

Drug Molecules

M&A

View all Roundtables

Alcami’s simplified, entirely U.S.-based supply chain is one of our core strengths. At every phase of the product life cycle, risks are inevitable; this is especially true as supply chain complexities increase due to COVID-19.

Yadira Salamander
Director of Engineering Services, Alcami

The COVID-19 pandemic has highlighted the critical role that procurement plays in managing the supply of goods and services, especially in times of crisis. Business continuity planning has been used to great effect and has reinforced the need to keep plans live and regularly updated.

David Duff
VP Procurement, Vectura

At BASF Nutrition and Health, global, regional, country, and site crisis-management teams are meeting regularly to further monitor the outbreak of COVID-19 and recommend the necessary mitigation measures.

David Freidinger
Vice President of Pharma Solutions Business

The COVID-19 pandemic has provided many lessons and inspiration for improvement related to areas from people to processes and systems.

Brian Albright
Global Manufacturing and Supply Chain Leader, Pharma Solutions, DuPont Nutrition & Biosciences

The continuous optimization of operational fitness has always been an integral part of Rentschler Biopharma’s strategy. We have been closely monitoring and improving our processes, business continuity, and digital maturity, even before the outbreak of the COVID-19 pandemic.

Wolfram Schulze
Vice President Information Systems, Organization, & Digital Transformation and Head of Infection Prevention Task Force, Rentschler Biopharma

View All Answers

Our biggest focus is in digitalization and investing across our business to enable a virtual world, which enables faster decision-making and more efficient solutions that can help address cost profiles throughout the industry.

Brian Albright
Global Manufacturing and Supply Chain Leader, Pharma Solutions, DuPont Nutrition & Biosciences

In acknowledgment of our essential role in the value stream of drug development and manufacturing, we continuously strive to excel at each discipline within our service portfolio.

Wolfram Schulze
Vice President Information Systems, Organization, & Digital Transformation and Head of Infection Prevention Task Force, Rentschler Biopharma

Although drug pricing is ultimately up to the pharmaceutical and biopharmaceutical companies, we are taking steps at PCI to simplify the supply chain to help drug companies realize more efficiencies.

Brad Payne
Chief Operating Officer, PCI Pharma Services

Although CDMO costs related to APIs and drug products often represent only a small percentage of the final drug price, Hovione invests continuously in technologies and processes to improve customer value.

Jean-Luc Herbeaux, Ph.D.
Chief Operations Officer, Hovione

In November 2019, BASF launched our Virtual Pharma Assistants, a suite of cutting-edge tools aimed at supporting the most critical elements of pharmaceutical manufacturing and catalyzing the process of formulation, qualification, and procurement of key ingredients in the manufacturing of pharmaceutical products.

David Freidinger
Vice President of Pharma Solutions Business Management, BASF

View All Answers

There has been a massive global response to the COVID-19 pandemic. Many pharmaceutical companies have been making significant efforts to develop tests, treatments, and vaccines for COVID-19. They are leveraging and sharing their profound scientific knowledge.

Thierry Durand, Ph.D.
Managing Director, Minakem

It has been impressive to see how fast the industry responded to the outbreak. Once the genome of the virus was discovered, many set out to shut down the viral replication with many different approaches.

Christa Myer
Senior Associate / Senior Pharmaceutical Specialist, CRB USA

The COVID-19 pandemic has unveiled the complex landscape of the pharmaceutical industry, highlighting its strengths and weaknesses.

Marco Taglietti
M.D., President & CEO, SCYNEXIS

The pharmaceutical and biopharmaceutical industries have responded promptly to the COVID-19 pandemic challenge by evaluating possible utilization of available drugs, speeding the clinical testing for the new application for drugs originally developed for diseases with similar clinical signs and complications, and looking into more innovative approaches.

Daria Donati, Ph.D.
Director, Business Development and Innovation, Cytiva

The pharmaceutical industry responded to the COVID-19 pandemic in a responsible manner and is fully supportive of efforts of various governmental agencies in responding quickly to the challenges this pandemic represents.

Madhu Shaik, Ph.D.
Executive Director of R&D & Technical Services, Alcami

View All Answers

Penicillin has had a significant impact on society and the pharmaceutical industry. As the first true antibiotic, it ushered in advances in therapeutic medicine.

Andrew Bulpin, Ph.D.
Head of Process Solutions, MilliporeSigma

Improvements in quality of life have largely come about through small, incremental advances in scientific understanding, translated into products and policies over many decades.

Adrian Wildfire
CEO, CHIMagents

In my view, the three drug types that have had the greatest impact on society are beta-lactam antibiotics, monoclonal antibodies, and beta-agonists, either for asthma or for cardiovascular disease.

Chris Moreton, Ph.D.
Vice President, Pharmaceutical Sciences, FinnBrit Consulting

Platform technologies that allow for the therapeutic delivery and actuation of genetic therapy will continue to transform medicine, with the greatest impact yet to be seen.

Jake Becraft, Ph.D.
Chief Executive Officer & Co-Founder, Strand Therapeutics

As companies develop new treatments and vaccines and repurpose older drug products to fight COVID-19, the importance of excipients used, either in (bio)processing or formulation, cannot be forgotten.

Suzanna Brown
Global Marketing, BASF Pharma Solutions

View All Answers

There is always going to be M&A going on in the biopharmaceutical space, given the ecosystem that exists between biotech and large pharma. It’s just part of doing business in our industry.

Anne Whitaker
Chief Executive Officer, Aerami Therapeutics

We’re excited about the pace of change both in terms of the number of new modalities and in the regulators’ approach, encouraging more development of therapies that answer unmet medical needs. And we’re starting to see the result of this in better patient outcomes.

Sarah Holland, Ph.D.
Head of Licensing, Lonza Pharma & Biotech

Due to its nature, the pharmaceutical industry will always see M&A activity. That is not likely to change anytime soon. However, the drivers behind it do change over time, based on the trends in the market.

Andrew Badrot
Chief Executive Officer, C2 PHARMA

The outsourcing industry is growing at an astonishing rate. There are still many M&A deals to be made as pharma companies offload legacy plants associated with traditional small molecule manufacturing, giving rise to consolidation and expansion.

Barbara Morgan, Ph.D.
Global Business Director, Pharmaceutical Solutions and General Manager, CDMO Division, Lubrizol Life Science Health

The average premiums at which companies were acquired is high, but the likelihood of recovering it via pricing of the end drugs is uncertain.

Dago Caceres
Global Strategic Marketing Leader, Pharma Solutions at DuPont

View All Answers